Are You in Control of Your Data

Premier™ C. difficile GDH Receives FDA Clearance

Meridian Bioscience, Inc., has received clearance from the FDA for its new Clostridium difficile immunoassay, Premier™ C. difficile GDH. This product expands the Company's existing portfolio of C. difficile tests and has been available in Europe and the rest of world since October of 2010.

The assay detects a common antigen produced by toxigenic and non-toxigenic forms of C. difficile bacteria. Premier™ GDH is used by laboratories that want to screen patients with diarrhea for both forms of C. difficile. To differentiate those patients at risk of disease with toxin-producing forms of C. difficile, GDH-positive samples should be re-tested with toxin-detecting tests such as Meridian's Premier™ Toxins A&B or ImmunoCard® Toxins A&B, or with a molecular amplification assay, such as Meridian's illumigene® C. difficile test.

Jack Kraeutler, Chief Executive Officer, commented, 'C. difficile can be a very dangerous infection that may lead to severe consequences for both patients and the healthcare institutions that care for them. Clearance of our new Premier™ C. difficile GDH test continues the Company's long history of breakthrough products for the detection and identification of C. difficile.

Meridian introduced its first latex based assay in March, 1990. Shortly thereafter, Meridian scientists confirmed that the 'latex-reactive protein' of C. difficile was in fact a glutamate dehydrogenase and not a toxin, as previously thought. Continuing innovation allowed Meridian to launch the first commercially available GDH enzyme immunoassay (ImmunoCard® C. difficile GDH) in January 1993 that was significantly more sensitive than the previous latex based tests. This third generation GDH assay, built on 20 years of C. difficile expertise, should set a new standard for GDH identification and, along with our toxin detection assays and our new illumigene® molecular platform, affirms our unique position as the one IVD Company that offers complete solutions for C. difficile detection.'

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source: Meridian Bioscience, Inc. View latest company information

Posted: June 28, 2011
Request Information
[will open your email client]

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed